Abstract | BACKGROUND AND AIMS: METHODS: Patients with SLE (n = 237), unclassified autoimmune disease (n = 51), and healthy controls (n = 294) were genotyped for CYP2B6*5 and CYP2C19*2. Associations between these alleles and achievement of complete or partial response, development of end-stage renal disease, and time to remission were determined. RESULTS: The frequencies of the variant alleles CYP2B6*5 and CYP2C19*2 were 6.3 % and 15.9%, respectively. CYP2C19*2 genotypes were more frequent among African Americans than European Americans, and CYP2B6*5 genotypes were more frequent among European Americans than African Americans. Among LN patients treated with cyclophosphamide (n = 36), there were no differences between those with or without these genotypes relative to the frequency of complete or partial remissions or time to remission. CONCLUSION: This retrospective analysis failed to show an association between CYP2B6*5 and CYP2C19*2 and treatment outcomes in LN. This suggests that genotyping for these CYP450 variants may not be useful in individualizing treatment for severe LN.
|
Authors | J Winoto, H Song, C Hines, H Nagaraja, B H Rovin |
Journal | Clinical nephrology
(Clin Nephrol)
Vol. 75
Issue 5
Pg. 451-7
(May 2011)
ISSN: 0301-0430 [Print] Germany |
PMID | 21543025
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Cyclophosphamide
- Aryl Hydrocarbon Hydroxylases
- CYP2B6 protein, human
- CYP2C19 protein, human
- Cytochrome P-450 CYP2B6
- Cytochrome P-450 CYP2C19
- Oxidoreductases, N-Demethylating
|
Topics |
- Adult
- Aryl Hydrocarbon Hydroxylases
(genetics)
- Cyclophosphamide
(therapeutic use)
- Cytochrome P-450 CYP2B6
- Cytochrome P-450 CYP2C19
- Female
- Humans
- Lupus Nephritis
(drug therapy, genetics)
- Male
- Middle Aged
- Oxidoreductases, N-Demethylating
(genetics)
- Polymorphism, Single Nucleotide
- Retrospective Studies
|